6-Methanesulfonyl-3,4-dihydro-2H-1,4-benzoxazin-3-one
CAS: 459190-08-0
Ref. 3D-JTA19008
| 25mg | 239.00 € | ||
| 250mg | 949.00 € |
Product Information
Ruxolitinib is a small molecule Jak1/Jak2 inhibitor that blocks the JAK-STAT signaling pathway, which is involved in the proliferation and survival of cancer cells. Ruxolitinib has been shown to be synergistic with 6-Methanesulfonyl-3,4-dihydro-2H-1,4-benzoxazin-3-one (MSD), a myeloproliferative neoplasm drug that inhibits protein synthesis by interfering with the function of RNA polymerase. The combination of these drugs may be an effective therapy for myeloproliferative neoplasms such as chronic myelogenous leukemia and polycythemia vera.
Chemical properties
Technical inquiry about: 3D-JTA19008 6-Methanesulfonyl-3,4-dihydro-2H-1,4-benzoxazin-3-one
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
